LEVEL OF GROWTH FACTOR IN TARGETED CHEMOEMBOLIZATION OF RENAL CELL CARCINOMA


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Aim. To assess the level of vascular growth factor in the tumor tissue, peritumorous area and in the renal vein during partial nephrectomy with intra-arterial chemoembolization with a targeted drug in patients with renal cell carcinoma. Materials and methods. The study is based on the results of partial nephrectomy with intraoperative arterial chemoembolization with the targeted drug bevacizumab in patients with clear cell renal cell carcinoma of T1aN0M0 stage. The level of vascular growth factor in the tumor tissue, parenchyma of the peritumorous area and in the renal vein before partial nephrectomy, during the compression of the renal pedicle and after intra-arterial administration of the targeted drug was evaluated. Results. The obtained results showed that acute renal ischemia causes an increase in the level of vascular growth factor in the tumor tissue by almost twice, in the parenchyma of the peritumorous zone by more than one and a half times and in the renal vein by 2.5 times. Intra-arterial administration of the drug bevacizumab reduces the concentration of vascular growth factor in the tumor itself by a quarter, in the peritumorous zone by less than 10 percent, and in renal vein by almost 4 times. Conclusions. The additional targeted chemoembolization prior to partial nephrectomy in renal tumors can improve recurrence-free and metastatis-free survival by inactivating vascular growth factor, a massive release of which occurs in acute kidney ischemia.

全文:

受限制的访问

作者简介

A. Maksimov

Republican Hospital №1 National Medical Center

Email: maximov_alex1971@mail.ru
Head of the Department of Urology Yakutsk, Russia

A. Martov

Federal Medical and Biological Center named after A.I. Burnazyan FMBA RF; Lomonosov Moscow State University; City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow

Email: martovalex@mail.ru
corresponding member of RAS, Ph.D., MD, professor, head of the Department of Urology and Andrology of Federal Medical and Biological Center named after A.I. Burnazyan FMBA RF, leading researcher of the Department of Urology and Andrology of Medical Scientific and Educational Center of Lomonosov Moscow State University, Head of the Urology Department of City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow” Moscow, Russia

E. Tapyev

Republican Hospital №1 National Medical Center

physician of medical and genetic center of GAU RS Yakutsk, Russia

参考

  1. Велиев Е.И., Богданов А.Б. Особенности метастазирования рака почки, хирургическое лечение рецидивов и метастазов. Практическая онкология. 2005;3(6):167-171.
  2. Чиссов В. П., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2007 г. М.: ФГБУ «МНИОИ им. П.А. Герцена». 2009:6-8.
  3. Motzer R.J., Bukowski R.M., Figlin R.A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113(7):1 552-1558. doi: 10.1002/cncr.23776.
  4. Алексеев Б.Я., Калпинский А.С. Сорафениб в последовательной терапии метастатического рака почки. Медицинский совет 2013;(5- 6):86-90.
  5. Zarrin B., Zarifi F., Vaseghi G., Javanmard S.H. Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance. J. Res. Med. Sci. 2017;22:117.
  6. Матвеев В.Б., Волкова М.И. Рак почки. Русский медицинский журнал 2007;(14):1094-1099.
  7. Nerich V., Hugues M., Paillard M.J. et al. Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. Onco Targets Ther. 2014;7:365-374. doi: 10.2147/OTT.S56370
  8. Piccirillo J.F., Tierney R.M., Costas I. et al. Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry. JAMA 2004;291(20):2441-2447. doi: 10.1001/jama.291.20.2441. PMID: 15161894.
  9. Чубенко В.А. Осложнения таргетной терапии. Практическая онкология 2010;11(3):192-202).
  10. Максимов А.В. Неустроев П.А. Способ баллонной химиоэмболизации и резекции злокачественных опухолей паренхиматозных органов. Патент РФ на изобретение № 2711549. Государственный реестр изобретений Российской Федерации. 17.01.2020.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2022
##common.cookie##